TOPページ
|
英語
日本語
|
CONNECT WITH US:
ホーム
JCNについて
サービス
お問い合わせ
会員企業ログイン
*
ホーム
プレスリリース
2021年12月03日 15時00分
Acumen Diagnostics' PCR capabilities to tackle Omicron COVID-19 variant
- Highly accurate, cost-effective, affordable PCR tests with 2 laboratories able to undertake 7000 tests daily
- PCR test kits able to detect COVID-19 positive cases including those infected with Omicron variant
- Homegrown medical technology company that is fully integrated to manufacture PCR test kits locally
- One of the few companies in Singapore with proprietary technology in testing
シンガポール, 2021年12月03日 - (JCN Newswire) - Homegrown medical technology Company, Acumen Diagnostics Pte. Ltd. ("Acumen Diagnostics" or the "Company"), a 51% owned subsidiary of Q&M Dental Group (Singapore) and 49% owned by Aoxin Q&M Dental, today announced that its proprietary, locally-manufactured polymerase chain reaction ("PCR") test kits Acu-Corona 2.0 and Acu-Corona Duplex are able to detect COVID-19 positive cases infected with the Omicron variant.
Dr Ong Siew Hwa, Executive Director of Aoxin Q&M Dental and Chief Executive Officer & Chief Scientist of Acumen Diagnostics said, "As the COVID-19 threat continues to evolve with the emergence of a potentially more transmissible variant, Omicron, highly-accurate and cost-effective COVID-19 testing becomes even more important to detect and help curb the spread of the virus.
With PCR tests remaining the gold standard to detect COVID-19, Acumen Diagnostics remains well-positioned to help Singapore tackle this new challenge posed by the virus, with our effective and affordable PCR test kits that are equipped to detect COVID-19 positive cases infected with Delta and Omicron, as well as our laboratory testing capabilities that can run 7000 tests daily. We will continue to contribute to national COVID-19 testing efforts to support Singapore's safe and sustainable re-opening."
In addition to detecting COVID-19 positive cases infected with the Delta variant, the Company's proprietary PCR test kits are able to detect COVID-19 positive cases infected with the Omicron variant as well.
The Acu-Corona 2.0 PCR test targets two COVID-19 genes - RdRp and E, while the Acu-Corona Duplex PCR test targets the E gene and S gene. The portion of the S gene targeted by the Acu-Corona Duplex PCR test does not contain any of the 32 mutations that occurred in the Omicron variant, hence it can detect the Omicron variant without any loss of sensitivity.
This proprietary technology used in PCR test kits and laboratory testing is developed and owned by Acumen Diagnostics. Being locally manufactured, the Company's test kits can be deployed quickly and are more cost-effective and allow for greater self-sufficiency, compared to that of its peers imported from overseas.
Acumen Diagnostics possesses deep technical capabilities and the supporting infrastructure in molecular diagnostics, spanning R&D, manufacturing, and clinical laboratory testing, with 2 laboratories that are able to process 7000 COVID-19 diagnostics tests daily.
About Acumen Diagnostics Pte. Ltd.
Acumen Diagnostics Pte. Ltd. ("Acumen Diagnostics") is a homegrown Singaporean, award-winning medical technology company. It is fully integrated with functions in research and development, manufacturing, as well as commercialisation of molecular diagnostics by distribution as well as conducting clinical laboratory testing services for (including but not limited to) infectious diseases, cancer, and COVID-19. It has also actively established frontline services such as COVID-19 on-site swabbing operations.
Acumen Diagnostics is a 51% subsidiary of SGX-listed Q&M Dental Group (Singapore) Limited (SGX: 1D4.SI) and 49%-owned by SGX-listed Aoxin Q&M Dental Group Limited (SGX: QC7.SI). For more information, please visit the company website at www.acumen-research.com.
For more information, please contact:
Waterbrooks Consultants Pte. Ltd.
+65 6958 8008,
query@waterbrooks.com.sg
Wayne Koo (M): +65 9338 8166,
wayne.koo@waterbrooks.com.sg
Derek Yeo (M): +65 9791 4707,
derek@waterbrooks.com.sg
Copyright ©2024 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
新着プレスリリース
UK's Largest EV Show Returns for 4th Edition Driving Innovation with Policy Leaders, Product Launches, and EV Innovations
2024年04月19日 21時03分
富士通、世界初 形式の異なる企業のデジタルアイデンティティー証明書を変換する技術を開発し欧州データスペースへの接続実証に成功
2024年04月19日 10時00分
ランドクルーザー、新型車"250"シリーズを発売
2024年04月18日 15時00分
Honda、「N-VAN」を一部改良し発売
2024年04月18日 15時00分
三菱重工と日本ガイシ、アンモニア分解ガスからの膜分離水素精製システムを共同開発
2024年04月18日 14時00分
PAREMINAが革新的な抗老化ソリューションを携えて、Beautyworld Tokyo 2024でアジア初上陸を発表
2024年04月18日 13時45分
富士通とオラクル、日本市場におけるデータ主権要件に対応するソブリンクラウドの提供に向け戦略的協業
2024年04月18日 11時00分
トヨタの新スポーツメディア「トヨタイムズスポーツ」始まる
2024年04月17日 15時00分
Microex Launches Web3.0 Financial Trading Solution - Pioneering Innovation in Financial Technology
2024年04月17日 15時00分
エーザイ、抗てんかん剤「フィコンパ(R)」の注射剤を新発売
2024年04月17日 10時00分
LEXUS、ミラノデザインウィーク2024に出展
2024年04月16日 18時00分
三菱商事、米国ルイジアナ州におけるDACプロジェクトへの参画について
2024年04月16日 14時00分
NEC、SBTiからNet-Zero目標の認定を取得
2024年04月16日 14時00分
「LEXUS OVERTRAIL CAMP 2024」を開催
2024年04月15日 13時30分
InnoEX promotes Hong Kong as international I&T hub
2024年04月13日 20時00分
三菱重工航空エンジン、航空エンジン向け燃焼器製造の「MHIAEL長崎工場」2期棟を竣工
2024年04月12日 08時00分
FBS Releases a Major Update to Mobile App: Everything Is Now in Users' Smartphone
2024年04月11日 23時08分
Atlas Lithium、三井物産から3,000万米ドルの戦略的投資およびオフテイク契約を獲得
2024年04月11日 22時00分
WizMediBio Signs Contract with the Wisconsin Alumni Research Foundation (WARF) for Botulinum Toxin Strain
2024年04月09日 19時03分
ボーイング、三菱重工業、SMBCアビエーションキャピタルが共同で委託した持続可能な航空燃料(SAF)に関するレポートを発表
2024年04月09日 18時00分
もっと見る >>